


In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated 21 June 2001, Applicants provide herewith an initial CRF, as requested in the Notice.

Applicants further submit a substitute paper copy of the Sequence Listing as provided under 37 C.F.R. §1.825 to update the Sequence Listing and to correct minor typographical errors uncovered by Applicants during the preparation of this paper. Specifically, Applicants have amended the "General Information" of the Sequence Listing to record the assigned "Current Application Number", and to delete the optional "Software" data entry. Applicants have also corrected typographical errors, replacing "gly" with "Gly,"; inserting a comma between "Leu" and "Pro"; and replacing "Ph" with "Phe" and "Net" with "Met" (as demarcated on Mark-up sheets 1, 2, and 3, respectively, provided herewith). These amendments cure obvious typographical errors. No new matter is introduced by these amendments.

As required under 37 C.F.R. §1.825(b) and §1.821(e), Applicants provide herewith the Sequence Listing in CRF. Applicants further provide herewith statements required under 37 C.F.R. §1.821(f) and (g) that the paper copy and computer readable form of the Sequence Listing are the same in content, and contain no new matter.

In view of the foregoing amendments and remarks, Applicants believe that their application is in compliance with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, and is in condition for allowance. Examination of the present application on the merits and allowance of the pending claims are, therefore, respectfully requested.

Respectfully submitted,




Leon R. Yankwich; Registration No. 30,237  
Kenneth P. Zwicker, PhD; Registration No. 43,310  
Attorneys for Applicants  
YANKWICH & ASSOCIATES  
130 Bishop Allen Drive  
Cambridge, Massachusetts 02139  
telephone: (617) 491-4343  
telefax: (617) 491-8801

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

July 23, 2001  
Date

Stephanie L. Leicht  
Stephanie L. Leicht



AMENDMENT BY INSTRUCTION TO REPLACE UNDER 37 C.F.R. §1.825:  
VERSION WITH MARKINGS TO SHOW CHANGES MADE

SEQUENCE LISTING

Inventor: [redacted]  
Attorney: Robert J. [redacted]

<110> PATENTS REPTILES FOR CAPSINOEMBRYONIC ANTIGEN, CEA

<130> Sequence Listing BYX-016.0 US

<140> US 09/541,345 [not yet assigned]

<141> 2556-04-03

<141> 117

[<15> Patent: Ver. 2.1]

<210> 1

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CEA binding polypeptide

<220>

<221> VARIANT

<222> (1)

<223> Xaa is Asn, Asp or is absent

<220>

<221> VARIANT

<222> (2)

<223> Xaa is Trp

<220>

<221> VARIANT

<222> (3)

<223> Xaa is Asp, Phe or Val

<220>

<221> VARIANT

<222> (5)

<223> Xaa is Asn, Glu or Met

<220>

<221> VARIANT

<222> (6)

<223> Xaa is Asn, Leu, Met or Phe

<220>

<221> VARIANT

<222> (7)

<223> Xaa is Asp, Gly, Ile, Lys, Phe or Thr

<220>

<221> VARIANT

<222> (8)

<223> Xaa is Ala, Gln, [gly] Gly, Lys or Thr

<210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Ala, Asn, Asp, Leu or Gly  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Gln, Leu or Gly  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Ala, Trp or Tyr  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Ala, Gly, His, Phe, Thr or Val  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Asn, Gln, Phe, Ser or Val  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Arg, Leu, Pro or Ser  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Leu, Ser, Trp or Tyr  
  
 <400> 1  
 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa  
 1 5 10 15  
  
 <210> 2  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence  
  
 <210>  
 <213> Description of Artificial Sequence: family of  
 preferred CFA binding moieties  
  
 <210>  
 <211> VARIANT  
 <212> PRT  
 <213> Xaa is Asn or Asp  
  
 <210>  
 <211> VARIANT

